Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0015000LC2
Wed, 20.09.2023
Mainz BioMed N.V.
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
BERKELEY, US – MAINZ, Germany – September 20, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, [ … ]
Wed, 13.09.2023
Mainz BioMed N.V.
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) [ … ]
Tue, 05.09.2023
Mainz BioMed N.V.
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
BERKELEY, US – MAINZ, Germany – September 5, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strateg [ … ]
Tue, 29.08.2023
Mainz BioMed N.V.
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4
BERKELEY, US – MAINZ, Germany – August 29, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic compan [ … ]
Tue, 22.08.2023
Mainz BioMed N.V.
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland
BERKELEY, US – MAINZ, Germany – August 22, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” [ … ]
Tue, 15.08.2023
Mainz BioMed N.V.
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023
ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023
BERKELEY, US – MAINZ, Germany – August 15, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz [ … ]
Tue, 01.08.2023
Mainz BioMed N.V.
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics
BERKELEY, US – MAINZ, Germany – August 01, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a m [ … ]
Tue, 01.08.2023
Mainz BioMed N.V.
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics
BERKELEY, US – MAINZ, Germany – August 01, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a m [ … ]
Tue, 18.07.2023
Mainz BioMed N.V.
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year
BERKELEY, US – MAINZ, Germany – JULY 18, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company spe [ … ]
Tue, 18.07.2023
Mainz BioMed N.V.
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year
BERKELEY, US – MAINZ, Germany – JULY 18, 2023 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company spe [ … ]